Tarsus Pharmaceuticals, Inc.
Clinical trials sponsored by Tarsus Pharmaceuticals, Inc., explained in plain language.
Develops therapies for ophthalmic and dermatologic conditions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye gel could ease rosacea symptoms Results expected Dec 2026 (estimated) May already have reported ↗
-
Could a single pill stop lyme disease before it starts?
Prevention OngoingThis study tests a new pill called TP-05 (lotilaner) to see if it can prevent Lyme disease in healthy adults who are often around ticks. The pill is already used in pets to kill ticks. Researchers will give either a low dose, high dose, or placebo to 700 volunteers and watch for …
Phase 2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
New eye gel could ease rosacea symptoms
Symptom relief By invitation onlyThis Phase 2 trial tests a gel called lotilaner for people with moderate to severe ocular rosacea, a condition causing red, irritated eyes. About 155 adults will receive either the gel or a placebo to see if it is safe and helps symptoms. The study is currently enrolling by invit…
Phase 2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC